Patents by Inventor Robert Kendall Morrison

Robert Kendall Morrison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER
    Publication number: 20160176977
    Abstract: A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.
    Type: Application
    Filed: September 29, 2014
    Publication date: June 23, 2016
    Inventors: Aya JAKOBOVITS, Arthur B. RAITANO, Mary FARIS, Rene S. HUBERT, Wangmao GE, Karen Jane Meyrick MORRISON, Robert Kendall MORRISON, Pia M. CHALLITA-EID
  • Nucleic acid molecules encoding antibody drug conjugates (ADC) that bind to 191P4D12 proteins
    Patent number: 9314538
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: April 19, 2016
    Assignees: AGENSYS, INC., SEATTLE GENETICS, INC.
    Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An
  • Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
    Patent number: 9308278
    Abstract: Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: April 12, 2016
    Assignee: Agensys, Inc.
    Inventors: Michael Torgov, Robert Kendall Morrison, Aya Jakobovits, Jean Gudas, Zili An
  • NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7 USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND OTHER CANCERS
    Publication number: 20160090411
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Application
    Filed: February 2, 2015
    Publication date: March 31, 2016
    Inventors: Aya JAKOBOVITS, Robert Kendall MORRISON, Arthur B. RAITANO, Pia M. CHALLITA-EID, Juan J. PEREZ-VILLAR, Karen Jane Meyrick MORRISON, Mary FARIS, Wangmao GE, Jean GUDAS, Steven B. KANNER
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
    Publication number: 20150306245
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: July 13, 2015
    Publication date: October 29, 2015
    Applicants: AGENSYS, INC., SEATTLE GENETICS, INC.
    Inventors: Daulet SATPAYEV, Robert Kendall MORRISON, Karen Jane Meyrick MORRISON, Jean GUDAS, Aya JAKOBOVITS, Michael TORGOV, Zili AN
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS
    Publication number: 20150238633
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: February 27, 2015
    Publication date: August 27, 2015
    Inventors: Robert Kendall MORRISON, Zili AN, Karen Jane Meyrick MORRISON, Josh SNYDER, Xiao-Chi JIA
  • Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
    Patent number: 9078931
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: July 14, 2015
    Assignees: AGENSYS, INC., SEATTLE GENETICS, INC.
    Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An
  • Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
    Patent number: 8968742
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: March 3, 2015
    Assignee: Agensys, Inc.
    Inventors: Robert Kendall Morrison, Zili An, Karen Jane Meyrick Morrison, Josh Snyder, Xiao-Chi Jia
  • Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
    Patent number: 8951744
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: February 10, 2015
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
  • Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
    Patent number: 8945570
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: February 3, 2015
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
  • Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
    Patent number: 8846043
    Abstract: A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: September 30, 2014
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Wangmao Ge, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Pia M. Challita-Eid
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS
    Publication number: 20140194601
    Abstract: Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: December 13, 2013
    Publication date: July 10, 2014
    Applicant: AGENSYS, INC.
    Inventors: Michael TORGOV, Robert Kendall MORRISON, Aya JAKOBOVITS, Jean GUDAS, Zili AN
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS
    Publication number: 20140072586
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: August 23, 2013
    Publication date: March 13, 2014
    Applicants: SEATTLE GENETICS, INC., AGENSYS, INC.
    Inventors: Robert Kendall MORRISON, Zili AN, Karen Jane Meyrick MORRISON, Josh SNYDER, Xiao-Chi JIA
  • NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER
    Publication number: 20140051838
    Abstract: A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.
    Type: Application
    Filed: October 21, 2013
    Publication date: February 20, 2014
    Applicant: AGENSYS, INC.
    Inventors: Aya JAKOBOVITS, Arthur B. RAITANO, Mary FARIS, Rene S. HUBERT, Wangmao GE, Karen Jane Meyrick MORRISON, Robert Kendall MORRISON, Pia M. CHALLITA-EID
  • NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7 USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND OTHER CANCERS
    Publication number: 20140051096
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Application
    Filed: October 26, 2012
    Publication date: February 20, 2014
    Applicant: Agensys, Inc.
    Inventors: Aya JAKOBOVITS, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
  • NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7 USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND OTHER CANCERS
    Publication number: 20140051145
    Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
    Type: Application
    Filed: October 26, 2012
    Publication date: February 20, 2014
    Applicant: Agensys, Inc.
    Inventors: Aya JAKOBOVITS, Robert Kendall Morrison, Arthur B. Raitano, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen Jane Meyrick Morrison, Mary Faris, Wangmao Ge, Jean Gudas, Steven B. Kanner
  • Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer
    Patent number: 8647826
    Abstract: A novel gene (designated 125P5C8) and its encoded protein, and variants thereof, are described wherein 125P5C8 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 125P5C8 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 125P5C8 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 125P5C8 can be used in active or passive immunization.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: February 11, 2014
    Assignee: Agensys, Inc.
    Inventors: Mary Faris, Pia M. Challita-Eid, Rene S. Hubert, Daniel E. H. Afar, Arthur B. Raitano, Wangmao Ge, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Aya Jakobovits
  • Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
    Patent number: 8637642
    Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: January 28, 2014
    Assignees: Seattle Genetics, Inc., Agensys, Inc.
    Inventors: Daulet Satpayev, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Jean Gudas, Aya Jakobovits, Michael Torgov, Zili An
  • Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
    Patent number: 8609092
    Abstract: Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: December 17, 2013
    Assignee: Agensys, Inc.
    Inventors: Michael Torgov, Robert Kendall Morrison, Aya Jakobovits, Jean Gudas, Zili An
  • Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
    Patent number: 8562989
    Abstract: A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: October 22, 2013
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Wangmao Ge, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Pia M. Challita-Eid